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1.Introduction
1.1. Definition and epidemiology of dialytic hypotension
Intradialytic hypotension is the most common complication of hemodialysis,occurring in up
to 33% of patients. There are two main clinical patterns of dialysis-associated hypotension :
the first is episodic hypotension (defined by a sudden drop of systolic blood pressure below
100 mmHg or at least 30 mmHg with accompanying clinical symptoms), that typically oc‐
curs during the later stages of dialysis sessions and is generally favored by excessive weight
gain ; the second is chronic persistent hypotension, which affects about 10% of long-term di‐
alysis patients [1, 2], most of whom experience frequent episodes of hypotension during di‐
alysis sessions, whereas some patients have permanent hypotension with low predialysis
systolic pressure, often less than 100 mmHg [3, 4]. Intradialytic hypotension not only causes
discomfort and has a negative impact on health-related quality of life but it may also ad‐
versely affect the outcome of chronic hemodialysis, reducing patients’ life expectancy and
favoring underdialysis [5-10]. According to recent data, low pre-dialytic systolic and diastol‐
ic pressures, like low post-dialytic systolic pressure and the occurrence of hypotensive epi‐
sodes during dialysis sessions, are associated with a significantly increased risk of death
[5-9]. Moreover, a recent Japanese study has shown a link between dialysis-related hypoten‐
sion and the occurrence of progressive frontal lobe atrophy [10]. The incidence of intradia‐
lytic hypotension is expected to grow with the increasing number of elderly and diabetic
patients and patients with cardiovascular disease who are now starting hemodialysis, to‐
gether with the use of long-term dialysis in an increasing number of hemodialyzed patients.
In addition, dialysis treatment time has had a tendency to decrease over the last two deca‐
des and all these situations are known to be risk factors for this phenomenon [2,3].
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1.2. Etiology and pathogenesis of dialytic hypotension
Several factors contribute to dialytic hypotension. These include too rapid fluid removal in
an attempt to reach dry weight, a rapid reduction in plasma osmolality which causes extrac‐
ellular water to move into cells, high interdialytic weight gain, anemia, poor nutritional sta‐
tus with hypoalbuminemia, autonomic neuropathy, anephric status, reduced pressor
response to vasopressor agents, reduced cardiac reserve, increased arterial stiffness, im‐
paired venous compliance, use of acetate rather than bicarbonate as a dialysate buffer, inges‐
tion of a meal immediately before or during the dialysis session, use of low sodium or high
magnesium concentrations in the dialysate, and intake before the dialysis session of anti-hy‐
pertensive medications that can impair cardiovascular stability (especially nitrate deriva‐
tives) [1-4, 11,12]. In a recent cross-sectionnal study of a cohort of 72 hemodialysis patients,
36 of whom suffered from dialysis-relatedchronic hypotension, cardiac diastolic dysfunction
was found to be associated with dialysis hypotension [13]. The excessive release of several
endogenous vasodilatators such as nitric oxide, adrenomedullin and adenosine, has been
implicated in the pathogenesis of dialytic hypotension, together with an imbalance in the
synthesis of the endogenous vasoconstrictors endothelin and vasopressin [14-17]. The imme‐
diate cause of intradialytic hypotension is acute central hypovolemia [2,4]. Frank hypoten‐
sion occurs when cardiovascular mechanisms do not adequately compensate for the blood
volume reduction resulting from the imbalance between the ultrafiltration rate and the plas‐
ma-refilling rate [12].
2. Management and prevention of dialytic hypotension
Management of intradialytic hypotension involves treating the acute episode and applying
measures to prevent future episodes [4,11,18]. The acute management of intradialytic hypo‐
tension includes the following measures : reducing or halting ultrafiltration, use of the Tren‐
delenburg position and often a reduction in the blood flow rate and use of volume
expanders, regardless of the underlying mechanism [4,11,18]. Normal saline is the most
widely used volume expander and has been advocated as first-line therapy for intradialytic
hypotension [4,11,18]. Commonly used second and third-line fluids are hypertonic saline,
dextran, hydroxyethyl starch (HES), mannitol, albumin and gelatin solutions [4,11,18,19].
Standard measures to prevent or alleviate intradialytic hypotension include accurate setting
of the dry weight, avoidance of modifiable factors known to favor this phenomenon (e.g. ex‐
cessively rapid fluid removal in an attempt to reach dry weight, anemia, poor nutritional
status with hypoalbuminemia, ingestion of a meal immediately before or during the dialysis
session, and intake before the dialysis session of anti-hypertensive medications) that can im‐
pair cardiovascular stability, adjustment of the dialysate sodium and/or calcium concentra‐
tion and temperature, use of initial ultrafiltration followed by standard (or isovolemic)
dialysis, use of sodium, and ultrafiltration modeling [1-4,14]. Among resistant patients, the
most effective strategies to prevent intradialytic hypotension are to increase the dialysis time
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(for example by using either short daily hemodialysis sessions or frequent nocturnal hemo‐
dialysis) or to switch to peritoneal dialysis [1-4,14].
3. Use of colloids in refractory dialytic hypotension
Recent studies have shown that human albumin is safe in intensive care unitsand can also
be useful in this setting in patients with acute renal failure secondary to sepsis or associated
with profound hypoalbuminemia [20]. As central hypovolemia is the initiating factor in the
pathogenesis of dialytic hypotension [2, 12], recent studies have hypothesized and analyzed
the potential benefit of systematic infusion of colloids -- 20% albumin or 4% gelatin -- during
dialysis sessions in hypotension-prone patients unresponsive to usual preventive measures
[21, 22]. Until recently, few studies have evaluated colloids and especially albumin as a pri‐
ming fluid for hemodialysis in septic patients or as preventive or curative therapy for hypo‐
tension-prone dialysis patients. Jardin and coworkers showed that infusion of 300 ml of
17.5% albumin as a priming fluid at the start of the dialysis session resulted in better ultrafil‐
tration and hemodynamic stability than saline infusion in patients with sepsis-induced
anuric acute renal failure ; these authors also showed that hypovolemia(as reflected indirect‐
ly by reduced left ventricular filling pressure), reduced cardiac output and the decline in
mean arterial pressure were better corrected by 17.5% albumin than by saline [23]. McLi‐
geyo first reported an improvement in hemodynamic parameters in four hemodialysis pa‐
tients with chronic persistent hypotension receiving systematic infusions of 100 ml of 25%
albumin [24]. More recently, Van der Sande and coworkers showed in nine cardiac-compro‐
mised hypotension-prone dialysis patients that 100 ml of 20% albumin and 100 ml of hy‐
droxyethyl starch preserved systolic blood pressure and relative blood volume better than
33 ml of 3% saline during a hypotensive episode [25]. However, the side effects of hydrox‐
yethyl starch (prolonged bleeding time, deposition of HES in various tissues and especially
the liver) preclude its use in this setting and it is now forbidden in France and in numerous
countries in dialysis patients [26, 27].
We recently conducted a single blind prospective cross-over study of systematic infusion of
200 ml of 20% albumin as compared to 200 ml of 4% gelatin in 10 patients on long-term bi‐
carbonate hemodialysis with refractory permanent hypotension (despite cool dialysate asso‐
ciated with sodium and ultrafiltration profiling, at an ideal dry weight assessed by
echocardiography) ; the study lasted 20 weeks [21]. We analyzed the effect of albumin and
gelatin infusions on systolic and diastolic pressure and the number of hypotensive episodes
by using the n-of-1 trial methodology and the Wilcoxon matched-pairs signed-ranks test
[21]. Statistical analysis of individual data showed that 20% albumin increased systolic pres‐
sure in 6 patients (p< 0.05 Wilcoxon test) whereas 4% gelatin improved systolic pressure in
only 2 patients (p< 0.05 Wilcoxon test) [21].
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Figure 1. Evolution of systolic blood pressure with 20% albumin and 4% gelatin infusions in improved patients ac‐
cording toRostoker G,et al. A pilot study of routine colloid infusion in hypotension-prone dialysis patients unrespon‐
sive to preventive measures. J Nephrol 2011; 24(02) : 208-217; *p<0.5 at Wilcoxon test, ***p<0.001 at Wilcoxon test,
****p<0.0001 at Wilcoxon test; The values are given as median with the 10th and 90th percentiles
Albumin infusions increased diastolic pressure in 4 patients (p< 0.05 Wilcoxon test) whereas
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Figure 2. Evolution of diastolic blood pressure with 20% albumin and 4% gelatin infusions in improved patients ac‐
cordingtoRostoker G,et al. A pilot study of routine colloid infusion in hypotension-prone dialysis patients unresponsive
to preventive measures. J Nephrol 2011; 24(02): 208-217; *p<0.05 at Wilcoxon test; The values are given as median
with the 10th and 90th percentiles
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The median number of hypotensive episodes (systolic pressure < 100 mmHg) fell significant‐
ly in 3 patients during 20% albumin infusion and in 2 patients receiving 4% gelatin (p< 0.05,
Wilcoxon test) [21]. Dialysis quality assessed by the Kt/V ratio and the relative blood volume
reduction were also stable, whereas ionic dialysance at the end of the dialysis session was
improved by albumin but not by gelatin (p< 0.05, repeated measure ANOVA) [21]. Thus,in
this single blind cross-over pilot study using n-of-1 methodology, we found that systematic
infusion of 20% albumin or 4% gelatin during hemodialysis sessions improved hemody‐
namic parameters (systolic blood pressure, diastolic blood pressure and the number of hy‐
potensive episodes) and the ultrafiltration rate in most hypotension-prone patients
unresponsive to usual preventive measures [21]. Albumin was proved to be superior to gel‐
atin; however, both colloids were ineffective in some patients, suggesting the need for care‐
ful and objective evaluation of these expensive therapeutics on an individual level [21].
4. Hemodynamic mechanisms of action of colloids in refractory dialytic
hypotension
In hemodialysis sessions, during ultrafiltration, the refilling rate is dependent on colloid os‐
motic pressure [28]. Therefore, systematic infusion of 20% albumin during the dialysis ses‐
sion and, to a lesser extent, 4% gelatin, would be expected to increase colloid osmotic
pressure, enhance plasma refilling and thus prevent an abrupt reduction in blood volume
and acute hypovolemia. Albumin has a water binding capacity of 18 ml per gram, and 200
ml of 20% albumin solution binds 720 ml of water for 6-8 hours, whereas 200 ml of 4% gela‐
tin binds only 200 ml of water for 4-5 hours [29, 30]. It is also tempting to postulate that col‐
loids counteract the reduced cardiac preload with both atrial and ventricular underfilling as
recently shown by Graziani and coworkers at the end of the ultrafiltration session in the
subset of patients with severe dialysis-related hypotension [31]. Finally, systematic infusion
of colloids could improve cardiac output in patients with diastolic dysfunction: the German
nephrologic school postulated in the late 1980s, and demonstrated in the early 1990s, that
left-ventricular hypertrophy was a risk factor for dialysis-related hypotension due to diastol‐
ic dysfunction [32-35]. In contrast to German nephrologists, we found no relationship be‐
tween diastolic dysfunction and left ventricular mass [13]. The latter finding might be
related to changes in the epidemiology of dialysis over the last two decades: patients in the
eighties had left ventricular hypertrophy related to both hypertension and uremic fibrosing
cardiomyopathy, promoted by a long history of chronic dialysis with cuprophane mem‐
branes, while dialysis patients are now older and have diabetes or cardiovascular diseases
(especially ischemic cardiopathy), which are known to cause left ventricular diastolic dys‐
function and diastolic heart failure [13]. In patients with a very long dialysis vintage left
ventricular enlargement is attributable to chronic volume and flow overload associated with
anemia, presence of arteriovenous fistulas, sodium, water and uremic toxins retention [36].
Several mechanisms are involved in the pathophysiology of dialytic hypotension secondary
to cardiac diastolic dysfunction: first, diastolic dysfunction in hemodialysis patients induces
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filling disturbances in diastole leading to systolic dysfunction especially a fall in stroke vol‐
ume during hypohydratation induced by rapid ultrafiltration or when plasma refilling com‐
pensatory mechanisms are deficient resulting in central hypovolemia and abrupt
hypotension: central hypovolemia in such cases could be counteracted by infusions of col‐
loids [37,38]. Second, these hearts have a limited ability to utilize the Franck-Starling mecha‐
nism during exercise or its counterpart such as a dialysis session. Such limited preload
reserve especially if coupled with chronotropic incompetence seen with advancing age lim‐
its cardiac output during exercise and dialysis sessions ; this leads to lactate accumulation
and functional abnormalities of the myocardium [37,38]. Third, a substantial number of pa‐
tients who have left ventricular hypertrophy with high wall thickness and a small end dia‐
stolic volume exhibit a low stroke volume and depressed cardiac output [35].
5. Modulation of oxidative stress and microinflammatory status by
colloids in refractory dialytic hypotension
Data on the association between inflammatory status and dialysis hypotension are scarce: To‐
mita and coworkers have shown in nine patients with a history of intradialytic hypotension
when compared with eight patients without dialysis associated hypotension a correlation be‐
tween the levels of CRP and IL6 and the maximum percent change in mean arterial pressure
over multiple dialysis sessions suggesting that dialysis hypotension may trigger inflamma‐
tion [39]. This is consistent with the finding of Bergamini et al who found a significant release
of TNF-alpha during hypotension episodes [40]. We recently hypothesized that frequent hy‐
potension episodes may induce a noxious inflammatory response mediated by oxidative
stress induced by ischemia-reperfusion phenomenon [22]. In a prospective cross-over study
(lasting 20 weeks) of routine infusion of 200 ml of 20% albumin versus 200 ml of 4% gelatin in
10 patients with refractory intradialytic hypotension, we analyzed the effect of 20% albumin
and 4% gelatin on microinflammatory status, oxidative stress, serum nitrite and nitrate levels
by analysis of variance [22]. A significant decrease in serum ceruloplasmin and serum C3 was
observed during the albumin period (p< 0.05, repeated measure ANOVA) [22]. A significant
decrease in serum hydrogen peroxide was seen during albumin and gelatin administration
(p< 0.01, repeated measure ANOVA) and a dramatic decrease in serum lipid peroxides was
observed during the albumin period only (p< 0.01, Friedman test) [22].
Serum lactoferrin, serum proinflammatory cytokines and serum nitrite and nitrate levels re‐
mained stable during the different periods of this pilot trial [22]. These results strongly sug‐
gest that the improvement in microinflammatory status observed in hypotension prone
dialysis patients may be related to the decrease in ischemia-reperfusion of noble organs by
infusions of colloids together with a specific reduction of oxidative stress by 20% albumin.
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** p < 0.01    Repeated measures ANOVA test with Dunnett's post-test.


















Figure 3. Concentration of serum hydrogen peroxide in patients with refractory dialytic hypotension treated by sys‐
tematic infusion of colloids during dialysis sessions, according to Rostoker G et al Modulation of oxydative stress and
microinflammatory status by colloids in refractory dialytic hypotension. BMC Nephrol 2011; oct 20; 12 (1): 58;
**p<0.01 Repeated measures ANOVA test with Dunnett’s post-test

















** p< 0.01  Non parametric ANOVA with Friedman test followed by Dunn's post-test.

























Figure 4. Concentration of serum lipid peroxides in patients with refractory dialytic hypotension treated by systematic
infusion of colloids during dialysis sessions, according to Rostoker G et al Modulation of oxydative stress and microin‐
flammatory status by colloids in refractory dialytic hypotension. BMC Nephrol 2011; Oct 20; 12 (1): 58 ; **p<0.01 Non
parametric ANOVA with Friedman test followed by Dunn’s post-test.; The values are given as mean + SEM
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6. Anti-inflammatory mechanisms of action of colloids in refractory
dialytic hypotension
In the aforementioned pilot study, C3 and ceruloplasmin were significantly lowered during
the albumin period but not during the gelatin period [22]. This is consistent with recent
studies using experimental models of hemorrhagic shock, which indicated that the type of
resuscitation fluid greatly influences proinflammatory responses and especially neutrophil
activation and nuclear factor-Kappa B gene transcription; albumin was found to be the least
proinflammatory fluid [41, 42]. Conversely, ex-vivo data suggest that uremia may also in‐
crease vascular permeability [43] which may be acutely raised during dialysis–associated
hypotension via released mediators such as adenosine aimed to preserve perfusion of the
noble organs [17]; in this setting, albumin may itself influence vascular integrity by binding
to the interstitial matrix and sub-endothelium and by altering the permeability of these lay‐
ers to large molecules and solutes; these effects may be mediated by the binding of arachi‐
donic acid to albumin and by polynitroxylated albumin, which inhibits xanthine-oxidase-
mediated adhesion of human neutophils to endothelial cells [44].
In this trial, serum hydrogen peroxide levels were significantly lowered during both the al‐
bumin and the gelatin periods, suggesting that the improvement in hemodynamic parame‐
ters by colloids reduces oxidative stress related to the ischemia-reperfusion of noble organs
that occurs during dialytic hypotension [22,45]. Besides this classical ischemia-reperfusion
mechanism, by analogy with heart failure, it was hypothesized that entry of bacterial endo‐
toxin during dialysis sessions might be the result of intermittent underperfusion of the intes‐
tine during dialysis-associated hypotension episodes leading to cardiac stunning and
oxydative stress [46,47,48]; thus in this setting, colloids may improve both systemic and in‐
testinal perfusion and reduce gut ischemia [22,46,47,48]. In the latter pilot study, serum lipid
peroxide levels were also significantly reduced only during the albumin period. This is con‐
sistent with data showing that human serum albumin and bovine serum albumin provide
protection from lipid peroxidation propagated by inorganic reactive oxygen species generat‐
ed from xanthine oxidase/hypoxanthine in artificial systems [49] and that persistent hypoal‐
buminemia in hemodialysis patients is associated with peroxidation of erythrocyte
membranes [50]. Moreover, albumin is the major extracellular source of reduced sulphydryl
groups, termed thiols which are avid scavengers of reactive oxygen and nitrogen species;in‐
this way albumin influences redox balance [51, 52]. All these data also strongly suggest that
dialytic hypotension may contribute by different ways to the overproduction of reactive
oxygen species seen in end-stage renal failure patients, a multifactorial process mainly relat‐
ed to uremia per-se, the hemoincompatibility of the dialysis system and trace amounts of en‐
dotoxin in the dialysate, gut ischemia and that colloids may indifferent mechanisms
counteract it [22, 53].
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7. Conclusions
Recent studies have shown that systematic infusions of 20% albumin and 4% gelatin during
hemodialysis sessions improve hemodynamic parameters and ultrafiltration rate in most
hypotension prone dialysis patients unresponsive to the usual preventive manoeuvers. An
improvement in microinflammatory status was observed in parallel, which might be related
to the decrease in both ischemia-reperfusion of noble organs, gut ischemia and oxidative
stress. Hyperoncotic 20% albumin was found to have greater anti-inflammatory and anti-ox‐
idative properties than 4% gelatin. Moreover, in the case of a new and expensive therapy
such as 20% albumin (cost of 200 ml 20% albumin : 80 Euros as compared to 4 Euros for 200
ml 4% gelatin, in France), n-of-1 trials can furnish powerful evidence for provision on an in‐
dividual basis, allaying managerial and medical fears as to the cost of frequently ineffective
therapies being applied to an expanding at-risk population. From a pragmatic point of view,
we advise practitioners to initiate first gelatin which is much less expensive when a treat‐
ment of systematic infusion of colloids is scheduled during dialysis sessions. Owing to its
high cost, hyperoncontic albumin should be considered as a second-line therapy.Further
well-designed controlled trials with a sufficient number of patients, of hyperoncotic 20% al‐
bumin and 4% gelatin in hypotension-prone dialysis patients are warranted to assess the
benefit of colloids infusions in dialytic refractory hypotension.
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